Form 4: Arcutis Biotherapeutics Executive Sells Shares After Option Exercise
SEC Form 4 Filing
An Arcutis Biotherapeutics executive, Patrick Burnett, sold shares after exercising stock options, according to a recent SEC filing.
Summary
- Patrick Burnett, a Senior Vice President and Chief Medical Officer at Arcutis Biotherapeutics, engaged in multiple transactions involving the company's stock.
- On November 14, 2024, Burnett sold 50,749 shares of common stock at a weighted average price of $10.2945 per share.
- On the same day, he exercised options to acquire 18,377 shares at $0 and then sold those shares at $10.2945 per share.
- On November 15, 2024, Burnett exercised options to acquire 100 shares at $0 and then sold those shares at $10.03 per share.
- Following these transactions, Burnett directly owns 128,669 shares of common stock and 234,523 stock options.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider trading activity, which is a normal part of the financial markets. There is no indication of positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.
Comparison to Industry Standards
- Executive stock option exercises and subsequent sales are a common practice in the biotechnology industry, often part of compensation packages.
- Similar transactions are regularly reported by executives at comparable companies such as Dermavant Sciences (DRMT) and Incyte Corporation (INCY).
- The volume of shares sold is not unusual for an executive at this level, and the prices are within the typical trading range for the stock.
Stakeholder Impact
- The transactions may have a minor impact on the stock price due to the increased supply of shares in the market.
- Shareholders may view the transactions as a normal part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 01/12/2024 | Date of grant of stock options that vest monthly from this date. |
| 11/14/2024 | Date of multiple transactions including sale of 50,749 shares and exercise and sale of 18,377 options. |
| 11/15/2024 | Date of exercise and sale of 100 options. |
| 11/18/2024 | Date of filing of the SEC Form 4. |
Keywords
Arcutis Biotherapeutics, ARQT, stock options, insider trading, SEC Form 4, equity securities, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.